June 24, 2022
Customer Poster
An Unbiased Multi-Omics Approach for the Detection of Pancreatic Cancer Biomarkers Utilizing Ion-Mobility Mass Spec and Nanoparticle-Based Proteograph Technology
This poster describes a multi-omics platform facilitating the evaluation of the global proteome and lipidome in a pancreatic cancer cohort and identified multiple putative biomarker candidates across analyte classes for early disease detection.
Introduction
- Pancreatic cancer is the seventh leading cause of cancer-related death worldwide and the third leading cause of cancer-related death in the USA.
- Pancreatic cancer typically results in poor disease prognosis at diagnosis since it usually goes undetected until the cancer has progressed to irreversible levels.
- Challenges in early detection have led to poor survival rates, highlighting the need for early diagnostic test development.
- Although some tests are available, none have enough sensitivity and specificity for diagnostic early detection of cancer (CA19-9) and can require invasive biopsies.
- Early detection of pancreatic cancer may lead to better prognosis with improved patient outcomes.
- With recent technological advancements, it is now possible to perform systems biology level analysis leveraging a multi-omics approach to survey thousands of unique potential biomarker molecules from blood.
- Combining these orthogonal ‘omics technologies is key to developing new early disease screening tests.
Discover Seer Technology Access Programs & Services
Easily explore the protein universe with Seer. Our service providers and in-house Seer Technology Access Center (STAC) empower your research, accelerating results and deciphering the proteome at unprecedented depth and scale. Answer biology’s most challenging questions — faster.
